Financhill
Sell
43

DERM Quote, Financials, Valuation and Earnings

Last price:
$7.15
Seasonality move :
0.65%
Day range:
$7.08 - $7.40
52-week range:
$3.54 - $8.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.68x
P/B ratio:
7.73x
Volume:
64.1K
Avg. volume:
157K
1-year change:
25.88%
Market cap:
$166.6M
Revenue:
$56.1M
EPS (TTM):
-$0.39

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DERM
Journey Medical
$19.5M -- 0.53% -- $9.75
CATX
Perspective Therapeutics
$162.9K -$0.31 -- -55.87% $14.1071
FBIO
Fortress Biotech
$19.3M -$0.24 -2.43% -57.53% $10.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.43 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DERM
Journey Medical
$7.15 $9.75 $166.6M -- $0.00 0% 2.68x
CATX
Perspective Therapeutics
$3.9800 $14.1071 $295.4M -- $0.00 0% 28.05x
FBIO
Fortress Biotech
$1.89 $10.00 $55.9M -- $0.00 0% 0.74x
NBY
NovaBay Pharmaceuticals
$0.69 $0.85 $4M -- $0.00 0% 0.16x
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.50 $7.00 $4.1M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DERM
Journey Medical
53.7% -0.001 18.33% 0.97x
CATX
Perspective Therapeutics
-- 1.363 -- --
FBIO
Fortress Biotech
72.36% 0.018 103.39% 1.49x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DERM
Journey Medical
$8.3M -$3.3M -22.96% -54.07% -24.22% -$2.8M
CATX
Perspective Therapeutics
-- -$21.8M -- -- -- -$26.2M
FBIO
Fortress Biotech
$8.3M -$22.3M -67.58% -- -168.82% -$19.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Journey Medical vs. Competitors

  • Which has Higher Returns DERM or CATX?

    Perspective Therapeutics has a net margin of -31% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -54.07% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
    CATX
    Perspective Therapeutics
    -- -$0.25 --
  • What do Analysts Say About DERM or CATX?

    Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 36.36%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 254.45%. Given that Perspective Therapeutics has higher upside potential than Journey Medical, analysts believe Perspective Therapeutics is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    DERM
    Journey Medical
    3 0 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is DERM or CATX More Risky?

    Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

  • Which is a Better Dividend Stock DERM or CATX?

    Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DERM or CATX?

    Journey Medical quarterly revenues are $13.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Journey Medical's net income of -$4.1M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Journey Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.68x versus 28.05x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DERM
    Journey Medical
    2.68x -- $13.1M -$4.1M
    CATX
    Perspective Therapeutics
    28.05x -- -- -$18.2M
  • Which has Higher Returns DERM or FBIO?

    Fortress Biotech has a net margin of -31% compared to Journey Medical's net margin of -80.55%. Journey Medical's return on equity of -54.07% beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
  • What do Analysts Say About DERM or FBIO?

    Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 36.36%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 429.1%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    DERM
    Journey Medical
    3 0 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is DERM or FBIO More Risky?

    Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.752, suggesting its more volatile than the S&P 500 by 75.204%.

  • Which is a Better Dividend Stock DERM or FBIO?

    Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

  • Which has Better Financial Ratios DERM or FBIO?

    Journey Medical quarterly revenues are $13.1M, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Journey Medical's net income of -$4.1M is higher than Fortress Biotech's net income of -$10.6M. Notably, Journey Medical's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.68x versus 0.74x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DERM
    Journey Medical
    2.68x -- $13.1M -$4.1M
    FBIO
    Fortress Biotech
    0.74x -- $13.1M -$10.6M
  • Which has Higher Returns DERM or NBY?

    NovaBay Pharmaceuticals has a net margin of -31% compared to Journey Medical's net margin of -49.65%. Journey Medical's return on equity of -54.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About DERM or NBY?

    Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 36.36%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Journey Medical has higher upside potential than NovaBay Pharmaceuticals, analysts believe Journey Medical is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    DERM
    Journey Medical
    3 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is DERM or NBY More Risky?

    Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock DERM or NBY?

    Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DERM or NBY?

    Journey Medical quarterly revenues are $13.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Journey Medical's net income of -$4.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Journey Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.68x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DERM
    Journey Medical
    2.68x -- $13.1M -$4.1M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns DERM or OGEN?

    Oragenics has a net margin of -31% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -54.07% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About DERM or OGEN?

    Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 36.36%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Journey Medical, analysts believe Oragenics is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    DERM
    Journey Medical
    3 0 0
    OGEN
    Oragenics
    0 1 0
  • Is DERM or OGEN More Risky?

    Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock DERM or OGEN?

    Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DERM or OGEN?

    Journey Medical quarterly revenues are $13.1M, which are larger than Oragenics quarterly revenues of --. Journey Medical's net income of -$4.1M is lower than Oragenics's net income of -$2.2M. Notably, Journey Medical's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.68x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DERM
    Journey Medical
    2.68x -- $13.1M -$4.1M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns DERM or TOVX?

    Theriva Biologics has a net margin of -31% compared to Journey Medical's net margin of --. Journey Medical's return on equity of -54.07% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DERM
    Journey Medical
    63.54% -$0.18 $46.5M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About DERM or TOVX?

    Journey Medical has a consensus price target of $9.75, signalling upside risk potential of 36.36%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Journey Medical, analysts believe Theriva Biologics is more attractive than Journey Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    DERM
    Journey Medical
    3 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is DERM or TOVX More Risky?

    Journey Medical has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock DERM or TOVX?

    Journey Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Journey Medical pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DERM or TOVX?

    Journey Medical quarterly revenues are $13.1M, which are larger than Theriva Biologics quarterly revenues of --. Journey Medical's net income of -$4.1M is higher than Theriva Biologics's net income of -$4.3M. Notably, Journey Medical's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Journey Medical is 2.68x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DERM
    Journey Medical
    2.68x -- $13.1M -$4.1M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock